%0 Journal Article
%T Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
%A Jianming Ying
%A Lei Guo
%A Li Liu
%A Lin Yang
%A Peng Song
%A Shugeng Gao
%A Tao Zhang
%A Weihua Li
%A Yutao Liu
%J SCIE-indexed Journal
%D 2019
%R 10.21037/28230
%X In recent years, the tyrosine kinase receptor mesenchymal-epithelial transition (MET) has become a target in non-small cell lung cancer (NSCLC). Crizotinib, a potent tyrosine kinase inhibitor (TKI) of anaplastic lymphoma kinase (ALK) and ROS1, has demonstrated its remarkable therapeutic effect in patients with MET amplified or MET exon 14 skipping mutated advanced-stage non-small-cell lung cancer in several previous reports (1-5). Methods to detect MET alteration includes immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS) and reverse transcription polymerase chain reaction (RT-PCR). Few cases reported response to crizotinib in advanced NSCLC patients according to the results of MET IHC staining. In this article, we report a case of crizotinib effectiveness in a pretreated patient with advanced lung adenocarcinoma detected as MET overexpression/FISH-negative/NGS-negative
%U http://tcr.amegroups.com/article/view/28230/html